LYDIA PINKHAM HERBAL (ethyl alcohol/herbal drugs)

There are 5 contraindications. Absolute contraindication.

Contraindication List
Diabetic coma
Hemochromatosis
Pregnancy
Seizure disorder
Urinary tract infection

There are 20 severe contraindications. Adequate patient monitoring is recommended for safer drug use.

Severe List
Alcohol use disorder
Cardiac arrhythmia
Chronic heart failure
Chronic iron overload due to repeated blood transfusions
Diabetes mellitus
Disease of liver
Diverticular disease
Esophageal dysmotility
Hemolytic anemia
Hemosiderosis
Hypertension
Hypokalemia
Invasive procedure on brain
Metabolic acidosis
Porphyria
Postpartum hemorrhage
Retinal vascular occlusion
Severe renal impairment
Shock
Ulcerative colitis

There are 6 moderate contraindications. Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.

Moderate List
Coronary artery disease
Disease of liver
Edema
Hypotension
Kidney disease with reduction in glomerular filtration rate (GFr)
Peptic ulcer

There are 10 severe adverse reactions.

More Frequent	Less Frequent
None.	None.

Rare/Very Rare
Ataxia Cardiac arrest Encephalopathy Hypertension Hypertonia Hypokalemia Muscle weakness in lower extremities Rhabdomyolysis Ventricular fibrillation Ventricular tachycardia

There are 18 less severe adverse reactions.

More Frequent	Less Frequent
Black stools Constipation Diarrhea Flatulence Nausea	Abdominal distension Acute abdominal pain Vomiting

Rare/Very Rare
Altered mental status Amenorrhea Headache disorder Lethargy Muscle weakness Myalgia Nausea Pseudoaldosteronism Vomiting Weight loss

During the first and second trimester of pregnancy, iron-deficiency anemia is associated with a twofold increased risk of premature delivery and a threefold increased risk of a low-birthweight delivery. Although iron supplementation during pregnancy has been shown to decrease the incidence of anemia, evidence on the effect of routine iron supplementation during pregnancy on adverse maternal and infant outcomes is inconclusive. Blood volume expands by about 35% during pregnancy, and growth of the fetus, placenta, and other maternal tissues increases the iron requirement threefold during the second and third trimesters of pregnancy to about 5 mg of iron daily.

Although menstruation ceases and iron absorption increases during pregnancy, most pregnant women who do not use iron supplements to meet increased iron requirements cannot maintain adequate iron stores, particularly during the last 2 trimesters. Following delivery, iron in the fetus and placenta are lost to the woman, although some of the iron in the expanded blood volume may return to blood stores. Among low-income pregnant women enrolled in health programs in the US, the prevalence of iron-deficiency anemia is 9, 14, and 37% during the first, second, and third trimesters, respectively.

While similar data currently are not available for all pregnant women in the US, the low dietary iron intake among US women of childbearing age, the high prevalence of iron deficiency and associated anemia among such women, and the increased iron requirements during pregnancy suggest that anemia during pregnancy may extend beyond low-income women. In addition, use of prenatal multivitamin and mineral supplements among African-Americans, native American and Alaskan Indians, women younger than 20 years of age, and those having less than a high school education is substantially lower than in the general US pregnant population. The principal reasons for the current lack of widespread adoption of a recommended iron supplementation regimen during pregnancy in US women may include lack of health-care provider and patient perceptions that iron supplements improve maternal and infant outcomes, complicated dose schedules, and adverse effects (e.g., constipation, nausea, vomiting).

However, adequate dietary iron intake and iron supplementation generally are recommended for primary prevention of iron deficiency during pregnancy. By employing low-dose (i.e., 30 mg of iron daily) regimens with simplified dose schedules (i.e., once-daily dosing), patient compliance may be improved; low-dose regimens have been shown to increase patient tolerance and are as effective as higher dosages (e.g., 60-120 mg iron daily) in preventing iron-deficiency anemia.

No enhanced Lactation information available for this drug.

No enhanced Geriatric Use information available for this drug.